Site Stability To Be Discussed By Panel, Possible Adv. Cmte. Meeting
This article was originally published in The Tan Sheet
Executive Summary
An expert panel to discuss site-specific stability is being formed by FDA in response to concerns expressed by the drug industry, Center for Drug Evaluation & Research Deputy Director for Pharmaceutical Sciences Roger Williams stated at the NDMA Manufacturing Controls Seminar in Philadelphia Oct. 8-9.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning